Qiaojianan

1、Educational Experience

(1) 2017/09-2020/12, China Pharmaceutical University, School of Pharmacy, Doctor

(2) 2014/09-2017/07, China Pharmaceutical University, Institute of Pharmaceutical Sciences, Master

(3) 2009/09-2013/07, China Pharmaceutical University, School of Pharmacy, Bachelor

2、Working Experience

(1) 2020/12-present, China Pharmaceutical University, School of Pharmacy, Assistant researcher

(2) 2020/12-present, China Pharmaceutical University, Postdoctoral

1. Yudi Deng; Zhijie Jiang; Yincheng Jin; Jianan Qiao; Shan Yang; Hui Xiong; Jing Yao; Reinforcing vascular normalization therapy with a bi-directional nano-system to achieve therapeutic-friendly tumor microenvironment, Journal of Controlled Release, 2021, 340: 87-101</br>

2. Jianan Qiao; Fengchun Tian; Yudi Deng; Yunkai Shang; Shijie Chen; Enhao Chang; Jing Yao; Bio-orthogonal click-targeting nanocomposites for chemo-photothermal synergistic therapy in breast cancer, Theranostics, 2020, 10(12): 5305-5321 </br>

3. Fengchun Tian; Fatima Zohra Dahmani; Jianan Qiao; Jiang Ni; Hui Xiong; Tengfei Liu; Jianping Zhou; Jing Yao; A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer, Acta Biomaterialia, 2018, 75: 398-412 </br>

4. Jianan Qiao; Tingfang Wang; Can Zhang; Design，synthesis and bioactivities of 4-( 3-sulfonylbenzene ) amino-6-formylpyrrole［2,3-d］pyrimidine derivatives, Journal of China Pharmaceutical University, 2017, 48(5): 554-562 </br>

5. Tingfang Wang; Xiaofei Liu; Meixi Hao; Jianan Qiao; Caoyun Ju; Lingjing Xue; Can Zhang; Design, synthesis and evaluation of pyrrolo [2,3-d] pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors, Bioorganic & Medicinal Chemistry Letters, 2016, 26(12): 2936-2941

(1) Pharmaceutical polymer materials and targeted drug delivery systems

(1) Jiangsu Provincial Department of Science and Technology, Youth Fund Project of Jiangsu Provincial Natural Science Foundation, Research on Intelligent Responsive Nanodrug Dual Blocking of Metabolic Reprogramming Based on KRAS Pathway to Enhance Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma, from July 1, 2022 to June 30, 2025, 200000 yuan, under researching, presided over</br>

(2) National Natural Science Foundation, General Program, 82173754, Research on iron death activation microbiota ablation nanodrug for blocking tumor microorganism symbiotic chain in breast cancer, from January 1, 2022 to December 31, 2025, 550000 yuan, under researching, participating</br>

(3) National Natural Science Foundation, Youth Fund Project, 81803457, Study on nanozonal delivery to reshape tumor metabolic homeostasis and promote tumor vascular normalization mediated by classical therapy, from January 1, 2019 to December 31, 2021, 210000 yuan, completed, participated</br>

(4) National Natural Science Foundation, Youth Fund Project, 81703585, The role and mechanism of vitamin D receptor as a molecular switch in regulating hepatic stellate cell activation, from January 1, 2018 to December 31, 2020, RMB 20.1 million, completed, participated